-
Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out'
Thursday, May 7, 2026 - 4:55am | 887Read More...On Wednesday, Nancy Pelosi Stock Tracker drew attention to an AI-powered portfolio's latest biotech wager after Claude AI opened a new position in Denali Therapeutics (NASDAQ:DNLI) ahead of its earnings report. Claude AI Makes Bold Denali Therapeutics Earnings Bet The AI-run portfolio, known as The...
-
Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring
Monday, November 17, 2025 - 4:52pm | 1056Read More...Something big is happening in healthcare, as pharma stocks have recently rallied on breakthrough AI developments that could reshape the entire industry. The Healthcare Select Sector SPDR Fund (NYSE:XLV) is having its third-best month against the S&P 500 since 1999, and a big part of that...
-
Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It
Tuesday, November 4, 2025 - 1:11pm | 478Read More...Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its drug pipeline. However, "Pharma Bro" Martin Shkreli said he still likes the stock. SRPT stock is crashing. See the real-time price...
-
Why Is Bone Biologics Stock Surging On Friday?
Friday, June 27, 2025 - 10:23am | 478Read More...Bone Biologics Corporation (NASDAQ:BBLG) stock is trading higher on Friday, with a session volume of 17.22 million compared to the average volume of 38.795K as per data from Benzinga Pro. The company filed a patent application with the U.S. Patent and Trademark Office (USPTO) for its preclinical...
-
What's Going On With Viking Therapeutics Stock On Wednesday?
Wednesday, June 25, 2025 - 1:01pm | 793Read More...Viking Therapeutics, Inc. (NASDAQ:VKTX) on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in oral and...
-
Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues
Tuesday, June 24, 2025 - 2:54pm | 736Read More...Amgen Inc (NASDAQ:AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, MariTide demonstrated up to...
-
Hims CEO Slams Novo Nordisk For 'Anticompetitive Demands' After Ozempic Maker Abruptly Ends Partnership: 'We Refuse To Be Strong-Armed'
Tuesday, June 24, 2025 - 3:06am | 899Read More...Hims & Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant. Check out the current price of HIMS...
-
Donald Trump Jr. Joins Mark Cuban In Slamming Elizabeth Warren on Healthcare Pricing
Saturday, June 21, 2025 - 11:46am | 626Read More...Donald Trump Jr. has joined billionaire entrepreneur Mark Cuban in publicly voicing disapproval of Sen. Elizabeth Warren (D-Mass.)’s approach to healthcare pricing. Despite their political differences, Trump Jr. and Cuban found a common point of contention in Warren’s healthcare pricing...
-
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
Friday, June 20, 2025 - 5:59am | 1111Read More...A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices. What Happened: The clash, unfolding as of Friday, has reignited discussions on Pharmacy Benefit Managers (...
-
Bill Ackman Slams Subsidies For Contributing To $37 Trillion National Debt, Hails Trump's Drug Price Order
Monday, May 12, 2025 - 2:24am | 782Read More...Billionaire investor and the CEO of Pershing Square, Bill Ackman, flagged the contribution of various subsidies to the mounting U.S. debt and appreciated President Donald Trump for proposing an order to cut the drug prices, quoting his earlier suggestion. What Happened: In an X post, Ackman...
-
Roche's $50 Billion US Investment Commitment Includes New Facilities, 12,000 Jobs, Expanded R&D Hubs As Drug Tariffs Loom
Tuesday, April 22, 2025 - 5:53am | 347Read More...Roche Holdings AG (OTC:RHHBY) has revealed a $50 billion investment plan centering on manufacturing and research in the U.S., indicating a strategic change as potential drug tariffs loom. What Happened: The Swiss pharmaceutical giant will establish new and expanded facilities across Indiana,...
-
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Friday, April 11, 2025 - 4:36am | 1028Read More...Even as President Donald Trump paused the reciprocal tariffs for 90 days on Wednesday, he later confirmed in a conversation with reporters at his Oval Office that pharmaceutical companies would face tariffs. What Happened: The rally in pharma stocks was short-lived after the stocks reversed course...
-
Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4%
Thursday, November 28, 2024 - 2:34am | 356Read More...Shares of Century Therapeutics Inc (NASDAQ:IPSC) zoomed by 20.74% to $1.63 per share on Wednesday, which is the highest price move in nearly a month since Oct. 1. The shares also rose the most in over 11 months since Dec. 6, 2023, in a single day. Also read: Trump’s Tariff Threat To Canada...
-
April Showers On Wall Street: Miners, Utilities Emerge As Bright Spots In Gloomy Market
Tuesday, April 30, 2024 - 4:38pm | 1922Read More...As April comes to a close, it’s time to compile the rankings for the top-performing sector and industry exchange-traded funds of the month. Taking a broader look at the stock market, the S&P 500 Index, represented by the SPDR S&P 500 ETF Trust (NYSE:SPY), finished April on a downturn...
-
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
Tuesday, April 2, 2024 - 10:17am | 700Read More...Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. But, in a post-pandemic world, Pfizer and Moderna shares lost about 30% of their respective value over the...
















